10 Stocks Posting Monster Gains Amid Market Downfall

Page 3 of 3

4. Telus Corp. (NYSE:TU)

Telus Corp. saw its share price jump by 13.35 percent on Thursday to finish at $10.78 apiece, as investors resumed buying positions on expectations of a higher takeover offer amid a brewing bidding war between two Canadian telco giants.

This followed a comment from one of the bidders, Quebecor, on Thursday, slamming Telus Corp.’s (NYSE:TU) potential merger with its competitor, BCE Inc. or Bell Canada.

Quebecor said that while interest being shown by Bell Canada’s parent company in acquiring Telus Corp. would strengthen a three-player telecom market, their potential would not represent a positive outcome for consumers.

It can be recalled that Quebecor offered to take over Telus in June 2026, while the latter also held preliminary talks with Bell Canada for a potential merger.

In a statement earlier in the week, Telus Corp. said that it continues to explore other strategic alternatives after raising concerns and identifying risks associated with Quebecor’s proposal.

“With respect to the financial terms, the Board is not satisfied that the consideration offered under the proposal adequately reflects the value of Telus, its leading position in the Canadian telecommunications market, nor the value creation opportunities available to Telus through continued execution of Telus’ strategic plan,” the listed firm said.

3. Opendoor Technologies Inc. (NASDAQ:OPEN)

Opendoor Technologies grew its share price by 14.96 percent on Thursday to end at $1.46 apiece as investors loaded portfolios ahead of tomorrow’s expiration of three warrant series.

In a regulatory filing on the same day, Opendoor Technologies Inc. (NASDAQ:OPEN) said that its Series K, A, and Z warrants are nearing expiration without extension.

The upcoming warrant delisting could offer some relief to existing investors as it removes a potential source of future share dilution, with the company no longer obligated to issue additional shares.

Warrants aside, Opendoor Technologies Inc. earlier this year reported strong revenues in the third quarter of the year at $1.022 billion, or a 12 percent jump from the $915 million in the same period last year.

Net loss, however, widened by 142 percent to $218 million from $90 million year-on-year.

For the fourth quarter of the year, Opendoor Technologies Inc. is targeting revenues to grow at least 40 percent year-on-year, while adjusted EBITDA is targeted at a loss of $70 million to $85 million.

“We are driving to Adjusted Net Income positive by the end of 2026, measured on a twelve-month go-forward basis. We are currently behind, but we intend to catch up,” it said.

2. Anthropic PBC (NASDAQ:ANT)

AI startup Anthropic PBC made a blockbuster debut on the US stock market on Thursday, with its shares skyrocketing by 17.07 percent to close at $97.17 apiece, in what is now considered the largest initial public offering (IPO) in history, marking a new milestone for the artificial intelligence industry.

The Claude creator—which trades under the ticker symbol “ANT”—immediately opened 34 percent higher than its IPO price of $83, jumped by as much as 39 percent to hit $115.10, before paring gains toward the close. It was able to raise $81.3 billion in fresh funds following the successful sale of 980 million shares.

Anthropic PBC (NASDAQ:ANT) closed the day with an estimated fully diluted valuation of approximately $1.28 trillion, retreating from the $2 trillion valuation implied by its opening price.

The strong uptake signaled renewed investor confidence for the AI sector, which has been reeling from a series of setbacks, including higher interest rates, further dragged down by Jensen Huang’s resignation as chief executive officer of Nvidia Corp.

Several technology giants hold significant exposure to Anthropic, including Amazon and Google, which both own stakes of up to $100 billion.

Other firms, namely Microsoft, Nvidia, and Advanced Micro Devices also collectively own $26 billion in the firm.

1. Insmed Inc. (NASDAQ:INSM)

Shares of Insmed Inc. soared 20.58 percent on Thursday to close at $144.46 apiece following reports that French pharmaceutical firm Sanofi SA is planning to acquire the company in what could be the largest transaction so far in the biopharmaceutical industry.

A report by Bloomberg earlier in the day, citing people privy to the matter, said that Sanofi is currently in talks with its investment advisors to evaluate the potential transaction. The transaction is not yet guaranteed, with a decision potentially weeks away.

Neither party confirmed nor denied the report, but ADRs of Sanofi SA dropped by 2.25 percent during the day.

The report followed the appointment of former Sanofi SA Chief Executive Officer Paul Hudson as one of the newest independent members of its board of directors last month, alongside Utpal Koppikar, Finance chief of Verily Health.

The planned acquisition aligns with Sanofi SA’s efforts to expand its presence in the respiratory market, particularly through Insmed Inc.’s (NASDAQ: INSM) Brinsupri, an FDA-approved treatment for non-cystic fibrosis bronchiectasis, and Arikayce, an inhaled antibiotic for MAC lung disease.

In the third quarter of the year, Brinsupri alone accounted for $400.1 million of Insmed Inc.’s total revenues, propelling a jump of 1,324 percent from only $28.1 million registered in the same period last year.

Arikayce accounted for $124.4 million, or a jump of 9 percent from $114.3 million year-on-year.

READ NEXT: Billionaire Stanley Druckenmiller’s New AI Warning and Top 10 Stock Picks

Disclosure: None. Follow Insider Monkey on Google News.

Page 3 of 3